Kumpiro Siriluk, Sriuranpong Virote, Areepium Nutthada
Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand E-mail :
Asian Pac J Cancer Prev. 2016;17(9):4391-4394.
Platinum-based regimens are effective treatments for advanced non-small cell lung cancer (NSCLC), but the five-year survival rate is still less than 20%. One possible factor appears to be resistance involving polymorphisms in the CTR1 gene which plays an importance role in accumulation of platinum in the cytoplasm.
To establish both prevalence of CTR1 polymorphism and its impact on treatment related toxicity in Thai advanced NSCLC patients.
Thirty-two advanced NSCLC participants received carboplatin and gemcitabine during January to June 2016 at King Chulalongkorn Memorial Hospital (KCMH) were recruited for analysis of the CTR1 rs12686377 genotype. These participants were planning to be treated with platinum-based chemotherapy for at least two cycles.
Allele frequency of CTR1 polymorphism G?T was found to be 25%. The results showed that genetic polymorphism at CTR1 rs12686377 was associated with emesis side effects (P = 0.020) and neuropathic symptoms (P = 0.010). In addition, hematologic side effects in terms of anemia also tended to be related to this polymorphism.
This is the first study suggesting that polymorphism at CTR1 rs12686377 may be associated with toxicity from platinum-based regimens. Therefore, it could be a factor to aid in treatment decision-making.
铂类方案是晚期非小细胞肺癌（NSCLC）的有效治疗方法，但五年生存率仍低于20%。一个可能的因素似乎是耐药性，这涉及到CTR1基因的多态性，该基因在铂在细胞质中的积累中起重要作用。
确定泰国晚期NSCLC患者中CTR1多态性的患病率及其对治疗相关毒性的影响。
招募了2016年1月至6月期间在朱拉隆功国王纪念医院（KCMH）接受卡铂和吉西他滨治疗的32例晚期NSCLC患者，用于分析CTR1 rs12686377基因型。这些患者计划接受至少两个周期的铂类化疗。
发现CTR1多态性G?T的等位基因频率为25%。结果表明，CTR1 rs12686377的基因多态性与呕吐副作用（P = 0.020）和神经病变症状（P = 0.010）相关。此外，贫血方面的血液学副作用也倾向于与这种多态性有关。
这是第一项表明CTR1 rs12686377多态性可能与铂类方案毒性相关的研究。因此，它可能是有助于治疗决策的一个因素。
